SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the pricing of its upsized initial
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation
